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INTRODUCTION 
For many decades treatment of an acute disease or a 
chronic illness has been mostly accomplished by delivery 
of drugs to patients using various pharmaceutical dosage 
forms.Traditionally, the oral drug delivery has been 
popular as the most widely utilized route ofadministration 
among all the routes that have been explored for the 
systemic delivery of drugs. Conventional oral drug 
delivery systems are known to provide an immediate 
release of drug, in which one cannot control the release of 
the drug and cannot maintain effective concentration at the 
target site for longer time. The bioavailability of drug from 
these formulations may vary significantly, depending on 
factors such as physico-chemical properties of the drug, 
presence of excipient, various physiological factors such as 
the presence or absence of food, pH of the GI tract and GI 
motility. To overcome this limitation of oral route is 
replied by parenteral route. This route offers the advantage 
of reduced dose, targeting of site and avoiding GI stability, 
hepatic by-pass of drug molecule. In the recent years, 
pharmaceutical research has led to the development of 
several novel drug delivery systems. The role of drug 
development is to take a therapeutically effective molecule 
with sub-optimal physicochemical and/or physiological 
properties and develop an optimized product that will still 
be therapeutically effective but with additional benefits 
such a
1
. 
 Sustained and consistent blood levels within the 
therapeutic window 
 Enhanced bioavailability 
 Reduced interpatient variability 
 Customized delivery profiles 
 Decreased dosing frequency 
 Improved patient compliance Reduced side effects 
The drug release can be modulated by different ways but 
the most of novel drug delivery systems are prepared using 
matrix, reservoir or osmotic principle. In matrixsystems, 
the drug is embedded in a polymer matrix and the release 
takes place by partitioning of drug into the polymer matrix 
andthe surrounding medium. In contrast, reservoirsystems 
have a drug core surrounded by a rate controlling 
membrane. The osmotic systems utilize the principles of 
osmotic pressure for the delivery of drugs in both the 
routes oral as well as parenteral
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ADVANTAGES 
Osmotic pump based drug delivery is formulated due to its 
many benefits over conventional dosage forms, some of 
which are as follows 
3-5
: 
 The release rate of osmotic systems is highly 
predictable and can be programmed by modulating the 
release control parameters. 
 The delivery rate of zero-order is achievable with 
osmotic systems. 
 In the osmotic pump tablet frequency of dosing is 
reduced due to drug being released over a longer period 
of time unlike conventional tablets 
 Extended release of a large amount of highly water-
soluble drug by utilizing counter polymer in 
polyethylene oxides 
 This is extremely valuable for patients with chronic 
illnesses which require the plasma concentrations of a 
drug to be within its therapeutic range to avoid 
breakthrough symptoms, for example, overnight 
management of pain in terminally ill patients 
 The reduction or avoidance of side effects due to high 
plasma drug concentrations or ‘dose dumping   
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 Better control of therapeutic drug concentration. 
DISADVANTAGES 
Development costs: Expensive specialized equipment and 
inert ingredients may be required for osmotic pump tablet 
formulations.  
 Release rate: The drug release rate can be altered by 
food and gastric transit time; as a result differences 
may arise in the release rate between doses.  
 Can not crush or chew products: Osmotic pump tablet 
should not be crushed or chewed as it can lead to loss 
of the ‘slow release’ characteristics as well as 
toxicity.
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OSMOSIS  
Process of movement of the solvent from the 
lower concentration of solution to the higher concentration 
of the solution through the semipermiable membrane. 
Osmosis is the process that can control the drug delivery 
system. Osmotic pressure created due to imbibitions of 
fluid from external environment into the dosage form 
regulates the delivery of drug from osmotic device. Rate of 
drug delivery from osmotic pump is directly proportional 
to the osmotic pressure developed due to imbibitions of 
fluids by osmogen. Osmotic pressure is a colligative 
property of a solution in which the magnitude of osmotic 
pressure of the solution is independent on the number of 
discrete entities of solute present in the solution. Hence the 
release rate of drugs from osmotic dispensing devices is 
dependent on the solubility and molecular weight and 
activity coefficient of the solute (osmogent). 
7
 
Principal f Osmosis 
            The first report of an osmotic effect dates to 
Abbenollet (1748). But Pfeffer obtained the first 
quantitative measurement in 1877. In Pfeffer experiment a 
membrane permeable to water but impermeable to sugar is 
used to separate a sugar solution from pure water. A flow 
of water then takes place into the sugar solution that 
cannot be halted until a pressure π is applied to the sugar 
solution. Pfeffer showed that this pressure, the osmotic 
pressure π of the sugar solution is directly proportional to 
the solution concentration and the absolute temperature. 
Within few years, Vant Hoff had shown the analogy 
between these results and ideal gas laws by the expression  
π = Ф c r t  
Where Ф is the osmotic coefficient of the solution, c is the 
molar concentration of sugar in the solution, r is the gas 
constant, t is the absolute temperature.  
Osmotic pressure for concentrated solution of soluble 
solutes commonly used in controlled release formulation 
are extremely high ranging from 30 atm for sodium 
phosphate up to 500 atm for a lactose-fructose mixture, as 
their osmotic pressure can produce high water flow across 
semi permeable membrane. The osmotic water flow 
through a membrane is given by the equation  
Dv/dt = A Q Δ π/L  
Where dv\dt is water flow across the membrane of area A, 
thickness L, and the permeability  
Q in cm2 ,Δ π is the osmotic pressure difference between 
the two solutions on either side of the membrane.  
This equation is strictly for completely perm selective 
membrane that is membrane permeable to water but 
completely impermeable to osmotic agent.
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Basic Component of Osmotic System 
 Drug 
 Osmotic agent 
 Semipemiable membrane 
 Wicking agent 
 Pore forming agent 
 Coating agent 
Drug 
      All drugs are not suitable for osmotic system as 
prolong action medication .Drugs those which has 
biological half-life  more than 12 hr e.g.: Diazepam and 
drug which have very short half life i.e. less than 1 hr e.g. 
Penicillin G, furosemide are not suitable candidate for 
osmotic controlled release. Drug which have biological 
half-life in between 1 – 6 hrs and which is used for 
prolonged cure of diseases are ideal applicant for osmotic 
systems.  
9
 
Drug having following characteristics are suitable for 
formulation  
1. It should have short half-life  
2. Prolonged release of drug should be desired.  
3. It should be potent in nature.  
4. Solubility of drug should not be very high or very low. 
10
 
Osmotic agent  
These are also known as osmogens or osmogents and are 
used to create osmotic pressure inside the system. When 
the solubility of drug is low then the drug will show zero 
order release but at a slow rate. To enhance the release rate 
osmotic agent is added in the formulation. Osmotic agent 
creates a very high osmotic pressure gradient inside the 
system and increases release rate of drug.  
11
 
Some of the commercially used osmotic agents  
Sodium chloride, Fructose, sucrose, Potassium chloride, 
Xylitol, Sorbitol, citric acid, Dextrose, Manitole and 
Lactose. 
Some Mixture Used As a Osmotic Agent 
 Dextrose +Fructose 
 Lactose +Fructose 
 Sucrose+ Fructose 
 Lactose +Dextrose 
 Mannitol +Fructose 
 Mannitol +Dextrose 
 Dextrose +Sucrose 
 Mannitol +Sucrose12 
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Semi permeable Membrane  
     Since the membrane in osmotic systems is semi 
permeable in nature, any polymer that is permeable to 
water but impermeable to solute can be selected.
13
 
Cellulose acetate is a commonly employed semi permeable 
polymer for the preparation of osmotic pumps. It is 
available in different acetyl content grades. Particularly, 
acetyl content of 32% and 38% are widely used. Acetyl 
content is described by the degree of substitution (DS), i.e. 
the average number of hydroxyl groups on the 
anhydroglucose unit of the polymer replaced by 
substituting group. Some of the polymers that can be used 
for above purpose include cellulose esters such as cellulose 
acetate, cellulose diacetate, cellulose triacetate, cellulose 
propionate, cellulose acetate butyrate, and cellulose ethers 
like ethyl cellulose. 
14
 The Semi Permeable Membrane 
must meet some performance criteria;  
 The material must possess sufficient wet strength (-
105) and wet modulus so as to retain its dimensional 
integrity during the operational lifetime of the device.  
 The membrane exhibit sufficient water permeability 
so as to retain water flux rate in the desired range. 
The water vapor transmission rates can be used to 
estimate water flux rates.  
 The reflection coefficient and leakiness of the 
osmotic agent should approach the limiting value of 
unity. Unfortunately, polymer membranes that are 
more permeable to water are also, in general more 
permeable to the osmotic agent.  
 The membrane should also be biocompatible.15 
Wicking agent  
     The wicking agents are those agents which help to 
increase the contact surface area of the drug with the 
incoming aqueous fluid. The use of the wicking agent help 
to enhance the rate of drug released from the orifice of the 
drug. The examples are colloidal silicon dioxide, PVP & 
Sodium laryl sulphate. 
16
 
Pore Forming Agents  
     The pore-forming agents cause the formation of micro 
porous membrane. The micro porous wall may be formed 
in situ by a pore-former by its leaching during the 
operation of the system. The pore-formers can be inorganic 
or organic and solid or liquid in nature. For example, 
alkaline metal salts such as sodium chloride, sodium 
bromide, potassium chloride, potassium sulphate, 
potassium phosphate etc., alkaline earth metals such as 
calcium chloride and calcium nitrate, carbohydrates such 
as sucrose, glucose, fructose, mannose, lactose, sorbitol, 
and mannitol and, diols and polyols such as poly hydric 
alcohols, polyethylene glycols and polyvinyl pyrrolidone 
can be used as pore forming agents.
17
 
Coating solvents 
     The primary function of solvent system is to dissolved 
or dispersed the polymer and other additive and convey 
them to substrate surface. solvent used to prepare 
polymeric solution include inert inorganic and organic 
solvents that do not adversely harm the core ,wall and 
other material .the various types of solvents and their 
combinations are as follows: Methylene chloride, 
methanol, isopropyl alcohol, dichloromethane , ethyl 
acetate, acetone, carbon tetrachloride, cyclohexane, butyl 
alcohol, water etc and the mixture of solvents such as 
acetone-methanol(80:20), methylene chloride- methanol 
(79:21),acetone-ethanol(80:20), methylene chloride-
methanol-water (75:22:3) 
18
 
Mechanism of drug release 
     Tablet has rigid water permeable jacket with one or 
more laser dried small holes. As the tablet passes through 
the body the osmotic pressure of the tablet pushes the 
active drug through the opening in the tablet. The basic 
equation which applies to osmotic systems is  
dM/ dt= dV /dt.c ………(a) Where, 
dM /dt= mass release 
dV/dt  = volumetric pumping rate 
c = concentration of drug But, 
dV / dt= (A/ h)Lp 
(σ ΔΠ-Δp) Where, 
A= membrane area ,h= thickness of membrane ,Lp= 
mechanical permeability ,σ =reflection coefficient 
,ΔΠ=osmotic pressure difference ,Δp = hydrostatic 
pressure difference  
As the size of orifice delivery increases. 
 Δp decrease, so ΔΠ >> Δp and equation becomes dV / dt 
= A/ h Lp(σ ΔΠ) When the osmotic pressure of the 
formulation is large compared to the osmotic pressure of 
the environment, p can be substituted for Dp.  
dV / dt= A / h Lp 
σΠ = A / hk Π 
(k = Lpσ = membrane permeability) ,Now, equation (a) 
can be given as  
dM / dt = (A / h) k Π c = (A / h) k Π S (S = solubility of 
drug, c taken as S) 
 
Osmotic pump system : 
Table 1: Classification of Osmotic Pump Drug Delivery System
19
 
Implantable Oral osmotic Pump Specific types 
The Rose and Nelson Pump Single chamber osmotic pump:  Controlled porosity osmotic pump,  
Higuchi Leeper Pump Multi chamber osmotic pump:  Osmotic bursting osmotic pump,  
Higuchi Theuwes pump  Push pull osmotic pump,  
 Osmotic pump with non-expanding 
second chamber 
Liquid OROS,  
 
Kashmir et al                                     Journal of Drug Delivery & Therapeutics; 2013, 3(5), 156-162    159                                     
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Implantable Mini osmotic pump  Delayed Delivery osmotic system  
  OROS-CT (colon targeting),  
  sandwiched oral therapeutic system,  
  Osmotic pump for insoluble drugs,  
  Monolithic osmotic system and OSMAT  
 
Implantable Pump  
1. The Rose and Nelson Pump  
     In, 1955, two Australian physiologists reported the first 
osmotic pump. They were interested in delivery of drug to 
the gut of sheep and cattle. The pump consisted of three 
chambers a drug chamber with an orifice, a salt chamber 
with elastic diaphragm containing excess solid salt, and a 
water chamber. A semipermiable membrane separates the 
drug and water chamber. The difference in osmotic 
pressure across the membrane moves water from the water 
chamber in to the salt chamber.  The volume of chamber 
increases because of this water flow, which distends the 
latex diaphragm separating the salt and drug chambers, 
thereby pumping drug out of the device
20
 
2. Higuchi Leeper Pump 
     Higuchi Leeper pump is widely swallowed or 
implanted in the body of animal for delivery of antibiotic 
or growth hormones. Higuchi Leeper pump consist of rigid 
housing and semi permeable membrane. A layer of low 
melting waxy solid, such as microcrystalline paraffin wax 
is used in place of elastic diaphragm to separate the drug 
and osmotic chamber. Recent modification in Higuchi-
Leeper pump accommodated pulsatile drug delivery. The 
pulsatile release was achieved by the production of a 
critical pressure at which the delivery orifice opens and 
releases the drug.
21
 Pulsatile delivery could be achieved by 
using Higuchi Leeper pump; such modifications are 
described and illustrated in Figure. The Pulsatile release of 
drug is achieved by drilling the orifice in elastic material 
that stretches under the osmotic pressure. Pulse release of 
drug is obtained after attaining a certain critical pressure, 
which causes the orifice to open. The pressure then 
reduces to cause orifice closing and the cycle repeats to 
provide drug delivery in a pulsatile fashion. The orifice 
should be small enough to be substantially closed when the 
threshold level of osmotic pressure is not present
22
 
3. Higuchi -Theeuwes pump 
     In the early 1970s, Higuchi and Theeuwes6 developed 
another, even simpler variant of the Rose-Nelson pump. 
As with the Higuchi- Leeper pump, water to activate the 
osmotic action of the pump is obtained from the 
surrounding environment. In the Higuchi-Theeuwes 
device, however, the rigid housing is dispensed with and 
the membrane acts as the outer casing of the pump.  This 
membrane is quite sturdy and is strong enough to 
withstand the pumping pressure developed inside the 
device. The device is loaded with the desired drug prior to 
use. When the device is placed in an aqueous environment, 
release of the drug follows a time course set by the salt 
used in the salt chamber and the permeability of the outer 
membrane casing. Most of the Higuchi-Theeuwes pumps 
use a dispersion of solid salt in a suitable carrier for the 
salt chamber of the device 
23
 
4. Implantable Mini osmotic pump 
     Implantable Mini osmotic pump shown in figure 3 it is 
composed of three concentric layers-the drug reservoir, the 
osmotic sleeves and the rate controlling semi permeable 
membrane. The additional component called flow 
moderator is inserted into the body of the osmotic. The 
inner most compartment of drug reservoir which is 
surrounded by an osmotic sleeve, a cylinder containing 
high concentration of osmotic agent. The osmotic sleeve is 
covered by a semi permeable membrane when the system 
is placed in aqueous environment water enters the sleeve 
through semi permeable membrane, compresses the 
flexible drug reservoir and displaces the drug solution 
through the flow moderator. These pumps are available 
with variety of delivery rates between 0.25 to 10ml per 
hour and delivery duration between one day and four 
weeks 
24
 
Single chamber osmotic pump:-  
Elementary osmotic pump :- 
     Elementary osmotic pump was invented by Theeuwes 
in 1974 and it essentially contains an active agent having a 
suitable osmotic pressure, it is fabricated as a tablet coated 
with semi permeable membrane, usually cellulose acetate. 
25
 A small orifice is drilled through the membrane coating. 
(When this coated tablet is exposed to an aqueous 
environment, the osmotic pressure of the soluble drug 
inside the tablet draws water through the semipermeable 
coating and a saturated aqueous solution of drug is formed 
inside the device. The membrane is non-extensible and the 
increase in volume due to inhibition of water raises the 
hydrostatic pressure inside the tablet, eventually leading to 
flow of saturated solution of active agent out of the device 
through a small orifice.  
The pump initially releases the drug at a rate given by 
equation;  
dMt/dt = (dV/dt). Cs     Where, 
dV/dt depicts the water flow into the tablet   
Cs is the solubility of the agent inside the tablet.
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Fig 1: Elementary osmotic pump 
Multi chamber osmotic pump  
A. Push pull osmotic pump  
     Push pull osmotic pump is a modified EOP. Through, 
which it is possible to deliver both poorly water-soluble 
and highly water soluble drugs at a constant rate. This 
system resembles a standard bilayer coated tablet. One 
layer (depict as the upper layer) contains drug in a 
formulation of polymeric, osmotic agent and other tablet 
excipients. This polymeric osmotic agent has the ability to 
form a suspension of drug in situ. When this tablet later 
imbibes water, the other layer contains osmotic and 
colouring agents, polymer and tablet excipients. These 
layers are formed and bonded together by tablet 
compression to form a single bilayer core. The tablet core 
is then coated with semi permeable membrane. After the 
coating has been applied, a small hole is drilled through 
the membrane by a laser or mechanical drill on the drug 
layer side of the tablet. When the system is placed in 
aqueous environment water is attracted into the tablet by 
an osmotic agent in both the layers. The osmotic attraction 
in the drug layer pulls water into the compartment to form 
in situ a suspension of drug. The osmotic agent in the non-
drug layer simultaneously attract water into that 
compartment, causing it to expand volumetrically and the 
expansion of non drug layer pushes the drug suspension 
out of the delivery orifice.
26
 
B.    Osmotic Pump with Non Expanding Second 
Chamber  
     The second category of multi-chamber devices 
comprises system containing a non-expanding second 
chamber. This group can be divided into two sub groups, 
depending on the function of second chamber. In one 
category of these devices, the second chamber is used to 
dilute the drug solution leaving the devices. This is useful 
because in some cases if the drug leaves the oral osmotic 
devices a saturated solution, irritation of GI tract is a risk. 
Example: The problem that leads to withdrawal of 
osmosin, the device consists of a normal drug containing 
porous tablet from which drug is released as a saturated 
solution. However before the drug can escape from the 
device it must pass through a second chamber. Water is 
also drawn osmotically into this chamber either because of 
osmotic pressure of drug solution or because the second 
chamber contain, water soluble diluents such as NaCl. This 
type of devices consist of two rigid chamber, the first 
chamber contains a biologically inert osmotic agent, such 
as sugar or a simple salt like sodium chloride, the second 
chamber contains the drug. In use water is drawn into both 
the chamber through the surrounding semi permeable 
membrane. The solution of osmotic agent formed in the 
first chamber then passes through the connecting hole to 
the drug chamber where it mixes with the drug solution 
before exiting through the micro porous membrane that 
form a part of wall surrounding the chamber. The device 
could be used to deliver relatively insoluble drugs
27
 3. Specific types 
Table 2: Specific Types Osmotic Pump 
     TYPE               DESCRIPTION            STRUCTURE 
Controlled 
porosity 
osmotic pump 
The pump can be made with single or multicompartment 
dosage form, in either form, the delivery system comprises a 
core with the drug surrounded by a semipermeable membrane 
which has an asymmetric structure.When exposed to water, 
low levels of water-soluble additive are leached from 
polymer materials that were permeable to water yet remained 
insoluble. Then resulting sponge like structure formed the 
controlled porosity walls of interest and was substantially 
permeable to both water and dissolved drug agents.  
 
Semipermiable Membrane With Water 
Soluble Additives  
 
 
 
 
 
 
 
 
Drug Reservoir With Osmagens    
Figure 2: controlled porosity pump 
Osmotic 
bursting 
osmotic pump  
 
In this system delivery orifice is absent and size may be 
smaller. When it is placed in an aqueous environment, water 
is imbibed and hydraulic pressure is built up inside until the 
wall rupture and the content are released to the environment 
SEMIPERMIABLE MEMBRANE 
 
 
DRUG RESERVOIR 
Figure 3: Osmotic Bursting pump 
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Liquid OROS  Liquid OROS are designed to deliver drugs as liquid 
formulations and combine the benefits of extended release 
with high bioavailability. They are of three types: a) L OROS 
hard cap b) L OROS soft cap c) delayed liquid bolus delivery 
system.  
28
 
 
Sandwiched 
oral therapeutic 
system 
It is composed of polymeric push layer sandwiched between 
two drug layers with two delivery orifices. 
29
 
        
 
  
Osmotic pump 
for insoluble 
drugs 
The device concerns an osmotic agent for dispensing 
beneficial active agent that has poor solubility in water. The 
core of the system comprises a beneficial amount of a 
substantially water- insoluble active agent, which is lipid 
soluble or lipid- wettable; a sufficient amount of water 
insoluble lipid carrier, which is liquid at the temperature of 
use to dissolve or suspend the drug and agent to ensure the 
release of the lipid carrier of the drug from the pump. 
30
 
 
 
EVALUATION PARAMETER OF OSMOTIC DRUG 
DELIVERY FORMULATION:- 
Characterization of dosage form  
Effect of osmotic agents  
Swelling properties  
Membrane stability and thickness  
Orifice diameter and drug release  
In-vitro drug release study. 
31
 
The in vitro release of drugs from oral osmotic systems has 
been evaluated by the conventional USP paddle and basket 
type apparatus. 
The dissolution medium is generally distilled water as well 
as simulated gastric fluid (for first 2-4 h) and intestinal 
fluids (for subsequent hours) have been used. 
The standard specifications, which are followed for the 
oral controlled drug delivery systems are equivalently 
applicable for oral osmotic pumps. 
In vivo evaluation of oral osmotic systems has been carried 
out mostly in dogs. Monkeys can also be used but in most 
of the studies the dogs are preferred.
32
 
MARKET PRODUCTS:- 
Table 3: Products Incorporating ALZA's OROS® Technology 
BRAND NAME        SALT                                USED   
Alpress™ LP prazosin  For the treatment of hypertension.  
Cardura
®
 XL doxazosin mesylate for the treatment of hypertension 
Concerta methylphenidate HCl  Attention Deficit Hyperactivity Disorder 
Covera-HS verapamil Management of hypertension and angina pectoris.  
Ditropan XL oxybutynin chloride Overactive bladder. Symptoms of urge urinary incontinence, urgency and 
frequency.  
DynaCirc CR
®
 isradipine for the treatment of hypertension 
Efidac 24 chlorpheniramine  Allergy symptoms and nasal congestion.  
Glucotrol XL
®
 glipizide  for the control of hyperglycemia in patients with non-insulin-dependent 
diabetes 
Sudafed
®
 24 Hour pseudoephedrine nasal decongestant 
Procardia XL
®
 nifedipine For the treatment of angina and hypertension.  
Volmax albuterol  bronchospasm in patients with reversible obstructive airway disease          
 
CONCLUSION 
Osmotic pumps are the most reliable controlled drug 
delivery system. It uses osmotic pressure for controlled 
delivery of active agent. It allows targeted delivery of 
agents to virtually any tissue.  It ensures around the clock 
exposure to test agent at predictable levels. Osmotic 
pumps have excellence control on the drug delivery so 
these are mostly used now a days. 
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